ISCBH Bone School 2027
ISCBH HOME
Les Pensières Center for Global Health, Veyrier-du-Lac, Annecy, France, the venue for ICCBH Bone School 2023 on 29-31 May 2023

Registration and Fees

PLEASE NOTE: Due to the popularity of previous schools, the 2027 Bone School is operating an application system for delegates.  All applications should be submitted by 31 October 2026. 

Successful applicants will be notified at the end of November 2026 that they have a place at the School and will be sent a link to the registration form so that they can then select and pay for their place along with their accommodation. 

Fee includes:

  • Lunch and tea/coffee breaks on all 4 days of course
  • Attendance at all sessions and workshops
  • Informal Welcome Buffet Dinner on Monday 24 May
  • Group dinners on Tuesday 25 and and Thursday 27 May (Wednesday 26 May will be a free evening) 
  • Printed school programme book
  • Access to all course materials on line

* To download the Eligibility Form for the discounted rate please click here

Social Programme

Monday 24 May          

Delegates can join us for our Welcome buffet dinner depending on when they arrive or of course they may wish to visit nearby Annecy and have dinner there at their leisure.

Tuesday 25 May 
Group dinner at Les Pensieres included in the registration fee.

Wedneday 26 May 
Free Evening.

Thursday 27 May 
We will have a Group dinner at an nearby venue.  We will travel together into Annecy town for dinner.  This is also included in the registration fee.

Course refreshments

All coffee breaks and lunches as detailed in the programme during the four day course will be included in your registration fee.  The menus and style of lunches will change each day, but we have programmed an hour for lunch breaks on Tuesday, Wednesday and Thursday and on the final day we will run a buffet so that the lunch is flexible for delegates to have some food before their onward journey.

APPLICATIONS OPEN

Cancellation
If cancelled on or before 28 February 2027 – 100% of the registration fee is refundable.

If cancelled from 1 March to 31 March 2027 – 70% of the registration fee is refundable.

No refunds are payable from 1 April 2027 onwards

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

WEBSITE

At Kyowa Kirin, patients are at the center of everything we do. We are a global specialty pharmaceutical company dedicated to discovering and advancing innovative medicines for rare and hard-to-treat diseases where unmet need is greatest. Based in Japan with worldwide operations, we work across the continuum—from drug discovery to commercialization—guided by our commitment to patients and their families. Backed by more than 70 years of life sciences leadership, we focus on bone and mineral disorders, hemato-oncology, and rare diseases. Rooted in collaboration, we accelerate development through partnerships with industry, academia, patients, and healthcare providers. Learn more: KyowaKirin.com

WEBSITE

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

WEBSITE
BridgeBio Logo

At BridgeBio, our mission is to turn beautiful science into meaningful medicines for the people who need it most. BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations.

WEBSITE

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

WEBSITE

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

WEBSITE